A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer

International Journal of Clinical Oncology

Volumn 12, Issue 3, 2007, Pages 205-211

  Mori, Taisuke ^a   Hosokawa, Kenichi ^a   Kinoshita, Yoshiyuki ^a   Watanabe, Ai ^a   Yamaguchi, Takeshi ^a   Kuroboshi, Haruo ^a   Kato, Yoshiko ^a   Yasuda, Jinsuke ^a   Fujita, Hiroyuki ^a   Nakata, Yoshinori ^a   Honjo, Hideo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Docetaxel; Ovarian cancer; Paclitaxel; Quality of life; Toxicity

Indexed keywords

CARBOPLATIN; DOCETAXEL; PACLITAXEL;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOOT DISEASE; HAND DISEASE; HUMAN; JAPANESE; MOTOR DYSFUNCTION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY ADENOCARCINOMA; PARALYSIS; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SENSORY DYSFUNCTION; SURVIVAL RATE; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DRUG TOXICITY; FEMALE; HUMANS; JAPAN; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; PACLITAXEL; PILOT PROJECTS; QUALITY OF LIFE; SURVIVAL ANALYSIS; TAXOIDS;

EID: 34250641959     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-007-0656-z     Document Type: Article

References (21)

1. DG Decker TR Fleming GD Malkasian Jr 1982 Cyclophosphamide plus Cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma Obstet Gynecol 60 481 487
2. WP McGuire WJ Hoskins MF Brady 1996 Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1 6
3. MJ Piccart K Bertelsen K James 2000 Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results J Natl Cancer Inst 92 699 708
4. RF Ozols BN Bundy BE Greer 2003 Phase 3 trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study J Clin Oncol 21 3194 200
5. A Du Bois HJ Luck W Meier 2003 A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first line treatment of ovarian cancer J Natl Cancer Inst 95 1320 1330
6. JN Denis A Correa AE Greene 1990 An improved synthesis of the taxol side chain and of RP 56976 J Org Chem 55 1957 1959
7. I Ringel SB Horwitz 1991 Studies with RP56976 (taxotere): a semisynthetic analogue of taxol J Natl Cancer Inst 83 288 291
8. F Gueritte-Vogelein D Guenard F Lavelle 1991 Relationships between the structure of Taxol analogues and their antimitotic activity J Med Chem 34 992 998
9. B Chevallier P Fumoleau P Kerbrat 1995 Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer; a phase II trial of the Clinical Screening cooperative Group of the European Organization for Research and Treatment of Cancer J Clin Oncol 2 314 322
10. WW Ten Bokkel-Huinink AM Provc M Piccart 1994 A chemotherapy for advanced breast cancer; a study of the EORTC Early Clinical Trials Group Ann Oncol 6 527 532
11. T Cerny S Kaplan N Pavlidis 1994 Docetaxel (taxotere) is active in non-small cell lung cancer. A phase II trial of the EORTC-Clinical Trials Group Br J Cancer 70 384 387
12. G Catimel J Verweij V Mattijsen 1994 Docetaxel (taxotere); an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 533 537
13. A Sulkes J Smyth C Sessa 1994 Docetaxel (taxotere) in advanced gastric cancer; Results of a phase II clinical trial Br J Cancer 70 380 383
14. PA Vasey GC Jayson H Gabra 2004 Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma J Natl Cancer Inst 96 1682 1691
15. N Saijo M Shimoyama H Fukuda 2001 National Cancer Institute - Common Toxicity Criteria (NCI-CTC Version 2.0, April 30, 1999) ~ JCOG version 2 ~ (in Japanese) Gan To Kagaku Ryoho 28 1993 2027
16. Rustin AE Nelstrop P McClean 1996 Defining response of ovarian carcinoma to initial chemotherapy according to serum CA125 J Clin Oncol 14 1545 1551
17. R Yamamoto S Minobe M Kaneuchi 2002 A phase I/II study of carboplatin and paclitaxel in patients with epithelial ovarian cancer Jpn J Clin Oncol 32 128 134
18. PA Vasey R Atkinson R Coleman 2001 Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170 178
19. MJ Millward MJ Boyer M Lehnert 2003 Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients Ann Oncol 14 449 454
20. N Katsumata R Tsunematsu K Tanaka 2000 A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer. a Japanese co-operative study Ann Oncol 11 1531 1536
21. DF Cella DS Tulsky G Gray 1993 The Functional Assessment of Cancer Therapy scale: development and validation of the general measure J Clin Oncol 11 570 579